The ProVIDE study is a prospective, randomized, double-blind, sham controlled study evaluating the safety and effectiveness of the ProVee® Urethral Expander System for the treatment of lower urinary ...

Proportion of adult managed care organizations with availability varied from 24 to 100 percent for SGLT2 inhibitors, 0 to 99 percent for GLP-1 receptor agonists.

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Barriers contributing to underreporting of fatigue also include belief that symptom is sign disease is progressing and attempt to be a “good patient.” A cross-sectional study compared barriers to ...

Outbreak mainly affected members of communities with low measles vaccination coverage in New Mexico, Oklahoma, and Texas.

Combined use of SGLT2 inhibitors and GLP-1 receptor agonists also significantly increased the risk for falls. (HealthDay News) — Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is an independent ...

Measles may reestablish endemicity, with an estimated 851,300 cases over 25 years at current vaccination rates.

At univariable analysis, both anti-C1q antibodies and non-use of hydroxychloroquine predicted renal flares at baseline and 6 and 12 months. Proteinuria (24/h proteinuria and proteinuria 0.5 g/day or ...

This is the first randomized trial directly comparing pulse-modulated Holmium:YAG laser and thulium fiber laser treatment of kidney stones during ureteroscopy.

The CISTO study is the only going prospective study comparing radical cystectomy vs bladder-sparing options for high-grade NMIBC.

HIPAA-regulated entities are asked to take steps to ensure full compliance with the current HIPAA security requirements, like data backup.

Fibrate therapy may lower the risks of mortality and progression to end-stage kidney disease (ESKD), despite raising the risk for new onset stage 3 or higher chronic kidney disease (CKD), a new study ...